U.S. Markets close in 4 hrs 51 mins

Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Xenetic Biosciences, Inc. (NASDAQ:XBIO) for five years would be nursing their metaphorical wounds since the share price dropped 98% in that time. And it's not just long term holders hurting, because the stock is down 84% in the last year. Furthermore, it's down 70% in about a quarter. That's not much fun for holders.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

See our latest analysis for Xenetic Biosciences

Given that Xenetic Biosciences didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.


You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).

NasdaqCM:XBIO Income Statement, June 20th 2019

This free interactive report on Xenetic Biosciences's balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

While the broader market gained around 5.0% in the last year, Xenetic Biosciences shareholders lost 84%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 53% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.